TY - JOUR
T1 - Erratum
T2 - Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (Cell (2021) 184(21) (5309–5337), (S0092867421011016), (10.1016/j.cell.2021.09.020))
AU - Morad, Golnaz
AU - Helmink, Beth A.
AU - Sharma, Padmanee
AU - Wargo, Jennifer A.
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/2/3
Y1 - 2022/2/3
N2 - (Cell 184, 5309–5337; October 14, 2021) We have identified errors in Table 1 of the originally published version of this review. During preparation of Table 1, we mistakenly listed the all-cause event rate, rather than the indicated high-grade (3-5) treatment-related adverse event rate, for KEYNOTE-189/NCT02578680 and KEYNOTE-407/NCT02775435. Table 1 and references (PMIDs) related to the final reports of KEYNOTE-189/NCT02578680 and KEYNOTE-407/NCT02775435, which include treatment-related adverse event rates, have now been corrected online. The authors apologize for any confusion these errors may have caused.
AB - (Cell 184, 5309–5337; October 14, 2021) We have identified errors in Table 1 of the originally published version of this review. During preparation of Table 1, we mistakenly listed the all-cause event rate, rather than the indicated high-grade (3-5) treatment-related adverse event rate, for KEYNOTE-189/NCT02578680 and KEYNOTE-407/NCT02775435. Table 1 and references (PMIDs) related to the final reports of KEYNOTE-189/NCT02578680 and KEYNOTE-407/NCT02775435, which include treatment-related adverse event rates, have now been corrected online. The authors apologize for any confusion these errors may have caused.
UR - http://www.scopus.com/inward/record.url?scp=85123771612&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2022.01.008
DO - 10.1016/j.cell.2022.01.008
M3 - Comment/debate
C2 - 35120665
AN - SCOPUS:85123771612
SN - 0092-8674
VL - 185
SP - 576
JO - Cell
JF - Cell
IS - 3
ER -